Diego Fonstad
Gründer bei Bullet Biotechnology, Inc.
Profil
Diego Fonstad is the founder of Sutro Biopharma, Inc. (founded in 2004) and Bullet Biotechnology, Inc. (founded in 2011).
At Sutro Biopharma, he held the title of Vice President-Operations.
At Bullet Biotechnology, he held the title of Director.
Mr. Fonstad has an undergraduate degree from Harvard University and an MBA from Stanford University.
Aktive Positionen von Diego Fonstad
| Unternehmen | Position | Beginn |
|---|---|---|
Bullet Biotechnology, Inc.
 Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Gründer | 01.09.2011 |
Ehemalige bekannte Positionen von Diego Fonstad
| Unternehmen | Position | Ende |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Gründer | - |
Ausbildung von Diego Fonstad
| Harvard University | Undergraduate Degree |
| Stanford University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Health Technology |
